Abstract

Cancer immunotherapy has been predominantly focused on biologically based intervention strategies. However, recent advances in the understanding of tumour–host interactions at the molecular level have revealed targets that might be amenable to intervention with small-molecule inhibitors. In particular, key effectors of tumoral immune escape have been identified that contribute to a dominant toleragenic state that is suspected of limiting the successful implementation of treatment strategies that rely on boosting immune function. Within the context of the pathophysiology of cancer-associated immune tolerance, this Review delineates potential molecular targets for therapeutic intervention and the progress that has been made in developing small-molecule inhibitors.

Author affiliations

1. Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA.
2. Incyte Corporation, Wilmington, Delaware 19880, USA.

Correspondence to: Alexander J. Muller¹ Email: MullerA@MLHS.ORG

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.